Clinical Trial Update: Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Medical University of Vienna | Conditions: HHT, Morbus Osler | Phase 2 | Status: COMPLETED